TDMS Study 05188-06 Pathology Tables
NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96 Route: SKIN APPLICATION Time: 05:02:39 Facility: Battelle Columbus Laboratory Chemical CAS #: 1300-72-7 Lock Date: 07/28/93 Cage Range: All Reasons For Removal: All Removal Date Range: All Treatment Groups: Include All a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96 Route: SKIN APPLICATION Time: 05:02:39 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 MG/KG 182 364 727 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 50 Early Deaths Natural Death 7 10 9 8 Moribund Sacrifice 12 7 9 6 Survivors Terminal Sacrifice 31 32 32 36 Missing 1 Animals Examined Microscopically 50 49 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Gallbladder (49) (17) (18) (50) Leiomyosarcoma, Metastatic, Intestine Small, Jejunum 1 (6%) Intestine Large, Cecum (50) (16) (18) (50) Leiomyosarcoma 1 (6%) Intestine Small, Jejunum (49) (16) (18) (50) Fibrosarcoma, Metastatic, Skin 1 (2%) Leiomyosarcoma 1 (6%) Liver (50) (49) (50) (50) Hemangioma 2 (4%) Hemangiosarcoma 1 (2%) 1 (2%) Hepatocellular Carcinoma 9 (18%) 10 (20%) 7 (14%) 8 (16%) Hepatocellular Carcinoma, Multiple 1 (2%) 3 (6%) 2 (4%) Hepatocellular Adenoma 10 (20%) 8 (16%) 14 (28%) 19 (38%) Hepatocellular Adenoma, Multiple 8 (16%) 9 (18%) 4 (8%) 9 (18%) Hepatocholangiocarcinoma 1 (2%) 1 (2%) 2 (4%) Histiocytic Sarcoma 3 (6%) 2 (4%) 2 (4%) 2 (4%) Leiomyosarcoma, Metastatic, Intestine Small, Jejunum 1 (2%) Mesentery (7) (6) (5) (12) Fibrosarcoma, Metastatic, Skin 1 (8%) Hemangioma 1 (8%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (14%) 1 (20%) 2 (17%) Histiocytic Sarcoma 1 (14%) 1 (17%) 1 (20%) Leiomyosarcoma, Metastatic, Intestine Small, Jejunum 1 (20%) Pancreas (50) (17) (18) (50) Fibrosarcoma, Metastatic, Skin 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (6%) Histiocytic Sarcoma 1 (2%) 1 (6%) 1 (6%) Leiomyosarcoma, Metastatic, Intestine Small, Jejunum 1 (6%) Page 2 NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96 Route: SKIN APPLICATION Time: 05:02:39 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 MG/KG 182 364 727 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - cont Salivary Glands (50) (17) (18) (50) Stomach, Forestomach (50) (17) (18) (50) Squamous Cell Papilloma 2 (12%) Stomach, Glandular (50) (17) (18) (50) Carcinoma 1 (6%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (6%) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Blood Vessel (50) (17) (18) (50) Aorta, Hepatocholangiocarcinoma, Metastatic, Liver 1 (6%) Heart (50) (17) (18) (50) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (6%) Histiocytic Sarcoma 2 (4%) 1 (6%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (50) (17) (18) (50) Hepatocholangiocarcinoma, Metastatic, Liver 1 (6%) Capsule, Adenoma 1 (2%) 1 (2%) Adrenal Medulla (50) (17) (18) (48) Pheochromocytoma Benign 1 (2%) Islets, Pancreatic (50) (17) (18) (50) Adenoma 1 (2%) 1 (6%) Carcinoma 1 (2%) Pituitary Gland (50) (17) (18) (49) Meningioma Malignant, Metastatic, Brain 1 (6%) Pars Distalis, Adenoma 7 (14%) 3 (18%) 1 (6%) 5 (10%) Pars Intermedia, Adenoma 1 (2%) 2 (4%) Pars Intermedia, Carcinoma 1 (2%) Thyroid Gland (50) (48) (50) (50) Follicular Cell, Adenoma 1 (2%) 5 (10%) 1 (2%) 6 (12%) Follicular Cell, Adenoma, Multiple 1 (2%) Follicular Cell, Carcinoma 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ Page 3 NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96 Route: SKIN APPLICATION Time: 05:02:39 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 MG/KG 182 364 727 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Clitoral Gland (49) (15) (15) (46) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Ovary (50) (17) (18) (49) Cystadenoma 1 (6%) 1 (2%) Fibrosarcoma, Metastatic, Skin 1 (2%) Hemangioma 1 (6%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (6%) Histiocytic Sarcoma 1 (2%) 1 (6%) 1 (6%) 1 (2%) Teratoma Benign 1 (2%) Uterus (50) (17) (18) (50) Hemangiosarcoma 1 (2%) Histiocytic Sarcoma 2 (12%) 1 (2%) Leiomyosarcoma, Metastatic, Intestine Small, Jejunum 1 (6%) Polyp Stromal 3 (6%) 1 (6%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (50) (17) (18) (50) Histiocytic Sarcoma 1 (2%) 2 (12%) Lymph Node (7) (3) (6) (6) Bronchial, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (17%) Inguinal, Histiocytic Sarcoma 1 (17%) Lumbar, Histiocytic Sarcoma 2 (67%) 2 (33%) Mediastinal, Hepatocholangiocarcinoma, Metastatic, Liver 1 (14%) 1 (17%) 1 (17%) Mediastinal, Histiocytic Sarcoma 1 (14%) 1 (33%) 1 (17%) Pancreatic, Histiocytic Sarcoma 1 (17%) Renal, Hepatocholangiocarcinoma, Metastatic, Liver 1 (17%) Renal, Histiocytic Sarcoma 1 (17%) 1 (17%) Thoracic, Fibrosarcoma, Metastatic, Skin 1 (14%) Lymph Node, Mandibular (49) (15) (15) (48) Carcinoma, Metastatic, Harderian Gland 1 (7%) Histiocytic Sarcoma 2 (4%) 1 (2%) Lymph Node, Mesenteric (48) (17) (17) (50) Fibrosarcoma, Metastatic, Skin 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (6%) 2 (4%) Histiocytic Sarcoma 2 (4%) 2 (12%) 1 (6%) 2 (4%) Leiomyosarcoma, Metastatic, Intestine Small, Jejunum 1 (6%) Spleen (50) (17) (18) (50) Hemangiosarcoma 1 (6%) 2 (4%) Histiocytic Sarcoma 3 (6%) 1 (6%) 1 (2%) Page 4 NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96 Route: SKIN APPLICATION Time: 05:02:39 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 MG/KG 182 364 727 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM - cont Thymus (38) (16) (16) (44) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (6%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (6%) 2 (5%) Histiocytic Sarcoma 1 (3%) 1 (2%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (50) (17) (16) (50) Carcinoma 1 (2%) Skin (50) (49) (50) (50) Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (2%) Subcutaneous Tissue, Hemangiosarcoma 1 (2%) Subcutaneous Tissue, Skin, Site of Application, Fibrosarcoma 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (50) (17) (18) (50) Osteosarcoma 1 (2%) Skeletal Muscle (1) (3) Fibrosarcoma, Metastatic, Skin 1 (33%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%) 2 (67%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (50) (17) (18) (50) Carcinoma, Metastatic, Harderian Gland 1 (6%) Histiocytic Sarcoma 1 (2%) Meningioma Malignant 1 (6%) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (50) (18) (18) (50) Alveolar/Bronchiolar Adenoma 4 (8%) 1 (6%) 2 (11%) 6 (12%) Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (6%) Carcinoma, Metastatic, Harderian Gland 1 (2%) 2 (11%) 1 (2%) Fibrosarcoma, Metastatic, Skin 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 2 (11%) 1 (6%) 3 (6%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (6%) 2 (4%) Histiocytic Sarcoma 3 (6%) 1 (6%) 2 (4%) Leiomyosarcoma, Metastatic, Intestine Small, Jejunum 1 (6%) Page 5 NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96 Route: SKIN APPLICATION Time: 05:02:39 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 MG/KG 182 364 727 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM - cont Leiomyosarcoma, Metastatic, Intestine Large, Cecum 1 (6%) Squamous Cell Carcinoma, Metastatic, Urinary Bladder 1 (2%) Mediastinum, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (6%) Nose (50) (17) (18) (50) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Eye (1) (2) Carcinoma, Metastatic, Harderian Gland 1 (50%) Harderian Gland (5) (2) (1) (3) Adenoma 2 (40%) 1 (33%) Carcinoma 1 (20%) 2 (100%) 1 (100%) 2 (67%) Bilateral, Adenoma 1 (20%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (50) (17) (18) (50) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 3 (6%) 2 (12%) Urinary Bladder (50) (17) (18) (50) Squamous Cell Carcinoma 1 (2%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(49) *(50) *(50) Histiocytic Sarcoma 3 (6%) 2 (4%) 2 (4%) 2 (4%) Lymphoma Malignant 8 (16%) 3 (6%) 3 (6%) 5 (10%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 6 NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96 Route: SKIN APPLICATION Time: 05:02:39 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 MG/KG 182 364 727 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 45 34 31 44 Total Primary Neoplasms 71 54 44 82 Total Animals with Benign Neoplasms 29 22 20 35 Total Benign Neoplasms 43 30 24 52 Total Animals with Malignant Neoplasms 25 22 18 26 Total Malignant Neoplasms 28 24 20 30 Total Animals with Metastatic Neoplasms 5 5 5 8 Total Metastatic Neoplasm 9 8 24 25 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 7 NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96 Route: SKIN APPLICATION Time: 05:02:39 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE 0 MG/KG 182 364 727 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 50 Early Deaths Natural Death 11 10 3 9 Moribund Sacrifice 7 3 8 6 Survivors Terminal Sacrifice 32 37 39 35 Animals Examined Microscopically 50 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Intestine Small, Jejunum (50) (12) (11) (50) Liver (50) (50) (50) (50) Hemangioma 2 (4%) 1 (2%) Hemangiosarcoma 2 (4%) 2 (4%) 1 (2%) Hemangiosarcoma, Multiple 3 (6%) 3 (6%) 2 (4%) 1 (2%) Hemangiosarcoma, Metastatic, Spleen 1 (2%) 1 (2%) 1 (2%) 3 (6%) Hepatoblastoma 4 (8%) 2 (4%) Hepatocellular Carcinoma 21 (42%) 17 (34%) 12 (24%) 15 (30%) Hepatocellular Carcinoma, Multiple 14 (28%) 14 (28%) 10 (20%) 11 (22%) Hepatocellular Adenoma 15 (30%) 21 (42%) 14 (28%) 13 (26%) Hepatocellular Adenoma, Multiple 22 (44%) 11 (22%) 7 (14%) 16 (32%) Hepatocholangiocarcinoma 1 (2%) Histiocytic Sarcoma 1 (2%) Osteosarcoma, Metastatic, Uncertain Primary Site 1 (2%) Mesentery (5) (4) Hemangiosarcoma, Metastatic, Spleen 1 (20%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (20%) Liposarcoma, Multiple 1 (25%) Pancreas (50) (13) (11) (50) Liposarcoma, Metastatic, Mesentery 1 (2%) Salivary Glands (50) (13) (11) (50) Stomach, Forestomach (50) (13) (11) (50) Squamous Cell Papilloma 1 (2%) 1 (2%) Stomach, Glandular (50) (13) (11) (50) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (50) (13) (11) (50) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (8%) Hemangiosarcoma, Metastatic, Spleen 1 (2%) Page 8 NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96 Route: SKIN APPLICATION Time: 05:02:39 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE 0 MG/KG 182 364 727 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM - cont Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (50) (12) (11) (50) Adrenal Medulla (50) (12) (11) (50) Pheochromocytoma Benign 2 (4%) Pituitary Gland (49) (12) (10) (50) Pars Distalis, Adenoma 1 (2%) Thyroid Gland (50) (13) (11) (50) Follicular Cell, Adenoma 2 (4%) 1 (9%) 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Epididymis (50) (13) (11) (50) Liposarcoma, Metastatic, Mesentery 1 (2%) Prostate (50) (13) (11) (50) Liposarcoma, Metastatic, Mesentery 1 (2%) Seminal Vesicle (50) (13) (11) (50) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (50) (13) (11) (50) Hemangiosarcoma 1 (9%) Hemangiosarcoma, Metastatic, Spleen 1 (2%) 1 (9%) Lymph Node (3) (2) (2) (3) Mediastinal, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (50%) Mediastinal, Hemangiosarcoma, Metastatic, Liver 1 (33%) Mediastinal, Hepatocholangiocarcinoma, Metastatic, Liver 1 (33%) Mediastinal, Histiocytic Sarcoma 1 (50%) Lymph Node, Mandibular (43) (7) (8) (42) Lymph Node, Mesenteric (50) (9) (10) (47) Hemangioma 1 (2%) 1 (2%) Hemangiosarcoma, Metastatic, Spleen 1 (2%) Spleen (50) (13) (12) (49) Hemangiosarcoma 2 (4%) 1 (8%) 1 (8%) 3 (6%) Page 9 NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96 Route: SKIN APPLICATION Time: 05:02:39 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE 0 MG/KG 182 364 727 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM - cont Hemangiosarcoma, Metastatic, Bone Marrow 1 (8%) Liposarcoma, Metastatic, Mesentery 1 (2%) Thymus (37) (11) (6) (34) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (9%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%) Histiocytic Sarcoma 1 (9%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Skin (50) (50) (50) (50) Subcutaneous Tissue, Fibrosarcoma 1 (2%) Subcutaneous Tissue, Skin, Site of Application, Hemangioma 1 (2%) Subcutaneous Tissue, Skin, Site of Application, Hemangiosarcoma 1 (2%) Subcutaneous Tissue, Skin, Site of Application, Histiocytic Sarcoma 2 (4%) Subcutaneous Tissue, Skin, Site of Application, Lymphoma Malignant 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Skeletal Muscle (3) Hepatocellular Carcinoma, Metastatic, Liver 1 (33%) Liposarcoma, Metastatic, Mesentery 1 (33%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (50) (13) (11) (50) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (50) (16) (15) (50) Alveolar/Bronchiolar Adenoma 12 (24%) 4 (25%) 2 (13%) 7 (14%) Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 2 (4%) Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (6%) 1 (7%) 1 (2%) Hemangiosarcoma, Metastatic, Spleen 1 (2%) Hepatoblastoma, Metastatic, Liver 2 (4%) Hepatocellular Carcinoma, Metastatic, Liver 12 (24%) 5 (31%) 7 (47%) 11 (22%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 1 (6%) Mediastinum, Alveolar/Bronchiolar Carcinoma, Page 10 NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96 Route: SKIN APPLICATION Time: 05:02:39 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE 0 MG/KG 182 364 727 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM - cont Metastatic, Lung 1 (6%) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Harderian Gland (2) (1) (3) Adenoma 1 (50%) 1 (100%) 1 (33%) Carcinoma 1 (33%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (50) (13) (11) (50) Hepatocellular Carcinoma, Metastatic, Liver 1 (8%) 1 (2%) Renal Tubule, Adenoma 1 (2%) Renal Tubule, Carcinoma 1 (2%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(50) *(50) Histiocytic Sarcoma 2 (4%) Lymphoma Malignant 5 (10%) 4 (8%) 6 (12%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 11 NTP Experiment-Test: 05188-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC SODIUM XYLENESULFONATE Date: 04/04/96 Route: SKIN APPLICATION Time: 05:02:39 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE 0 MG/KG 182 364 727 MG/KG MG/KG MG/KG ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 49 41 36 47 Total Primary Neoplasms 108 78 60 90 Total Animals with Benign Neoplasms 43 33 24 37 Total Benign Neoplasms 58 36 26 46 Total Animals with Malignant Neoplasms 39 33 28 33 Total Malignant Neoplasms 50 42 34 44 Total Animals with Metastatic Neoplasms 15 6 10 16 Total Metastatic Neoplasm 21 11 11 26 Total Animals with Malignant Neoplasms 1 Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 12 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------